ArticleAdvances in therapy2026
Real-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRuxolitinib cream has demonstrated efficacy and safety in patients aged ≥ 2 years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated that initiation of ruxolitinib cream may reduce the need for other AD therapies, both topical and systemic. This analysis investigated the longer-term (18-month) effect of ruxolitinib cream on AD treatment patterns.
methodsIn this retrospective, observational study, US claims data from the Healthcare Integrated Research Database (HIRD
resultsA total of 1269 patients were included in the analysis. The mean (SD; range) number of ruxolitinib cream fills during the 18-month follow-up period was 2.4 (2.3; 1-19). By months 13-18 of follow-up, claims for topical corticosteroids, topical calcineurin inhibitors, and topical PDE4 inhibitors were reduced from baseline by 52%, 63%, and 70%, respectively. Use of oral corticosteroids was reduced by 28%, with a 32% reduction in the mean cumulative prednisone-equivalent dose. Among patients with baseline biologic AD therapy (n = 231), 35.5% did not receive biologics during months 13-18 of follow-up. Additionally, among patients without baseline biologic use (n = 1038), > 90% remained off biologics.
conclusionUse of both topical and systemic AD therapies, including biologics, decreased over 18 months following initiation of ruxolitinib cream. These data suggest that ruxolitinib cream may reduce the need for additional topical therapies and limit escalation to systemic therapies for adults and adolescents with AD.
Indexed as
Identifiers
42554948What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.